## IT: Gartner, Inc. - XLK: Technology

### Executive Summary

No thesis match: MRS_10 0.5% below STRENGTH zone (3.0-6.0%); PEG 1.99 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-2.1% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($241.75)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 7
- **Sentiment:** Bullish (Bullish: 3, Bearish: 0)

**1. Highland Capital Management LLC Makes New Investment in Gartner, Inc. $IT**
- Source: MarketBeat | 20251227T114953 | Neutral | Relevance: 100%
- Highland Capital Management LLC recently initiated a new position in Gartner, Inc. (NYSE: IT) during Q3, acquiring 5,715 shares valued at approximately $1.50 million. This investment contributes to institutional investors collectively owning about 91.5% of Gartner's stock. The article also highlights a significant insider purchase by Director Stephen G. Pagliuca and a mixed outlook from analysts, with a consensus "Hold" rating despite Gartner beating Q3 EPS estimates.

**2. ZeOmega Recognized in 2025 Gartner(R) Market Guide for U.S. Healthcare Payer Care Management Workflow Applications**
- Source: Shreveport Times | 20251227T070847 | Somewhat-Bullish | Relevance: 100%
- ZeOmega has been recognized as a "Visionary Incumbent" in the 2025 Gartner Market Guide for U.S. Healthcare Payer Care Management Workflow Applications, a recognition they believe highlights their efforts to modernize payer care management amid evolving regulatory and technological demands. The company's Jiva Population Health Enterprise Management Platform addresses critical needs in healthcare by leveraging AI and analytics to automate workflows, identify at-risk populations, facilitate data exchange, and enhance member engagement. This acknowledgment affirms ZeOmega's commitment to providing advanced solutions that help health plans adapt to shifting policies, clinical standards, and member expectations, ultimately driving better outcomes.

**3. Gartner’s Relentless Rally: Can the Research Powerhouse Keep Beating the Market?**
- Source: AD HOC NEWS | 20251229T190154 | Bullish | Relevance: 100%
- Gartner Inc. has consistently outperformed the market due to its recurring revenue model and increased interest in AI-related insights. The company's stock has shown strong resilience, attracting institutional investors, though its premium valuation raises questions about future upside. Despite a bullish Wall Street outlook, investors must consider whether the current share price fully reflects its quality and growth potential.

**4. Reasons Why You Should Retain Gartner Stock in Your Portfolio.**
- Source: Yahoo Finance Singapore | 20251229T140827 | Bullish | Relevance: 100%
- Gartner (IT) stock has outperformed its industry over the past month, driven by its technologically advanced research segment and strategic acquisition of CEB Inc. The company's continuous efforts to enhance its AI-driven tool, AskGartner, and its consistent share buybacks further support its growth prospects. However, a key risk factor is its current ratio being lower than the industry average.

**5. Reasons Why You Should Retain Gartner Stock in Your Portfolio.**
- Source: TradingView — Track All Markets | 20251229T140750 | Bullish | Relevance: 96%
- Gartner (IT) stock has outperformed its industry recently, driven by its technologically advanced research segment and strategic acquisitions. The company's continuous innovation with AI tools like AskGartner and its valuable conference events contribute to client value. Despite a lower current ratio, consistent share buybacks indicate a commitment to shareholder value.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-17 | Morgan Stanley | $275 | $281 | -2% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-17 | Morgan Stanley | main | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 15 ($2.43M) |
| Sells | 7 ($0.21M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 55.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 9 / 1 |

**Top Holders:**
- Vanguard Group Inc: 14.0% (+5.3%)
- Blackrock Inc.: 10.6% (+0.5%)
- BAMCO Inc.: 6.0% (+18.3%)
- State Street Corpora: 4.9% (+2.8%)
- Independent Franchis: 4.4% (+100.0%)

### Key Risks

1. Elevated short interest (8.6%): bears positioning against stock.
2. Long-term trend broken: trading 21.6% below SMA200.
3. Falling knife pattern: rapid decline without stabilization, catch risk elevated.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.99 elevated, pricing in significant growth expectations. Forward P/E 18.9x stretched relative to 5% growth. Quality metrics strong (ROE 109%). Analyst sentiment negative (1 target cuts vs 0 raises). Insider buying signal ($2.4M), management confidence. Institutional flow bullish (9 buying vs 1 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $19.2B |
| Beta | 1.08 |
| 52W Range | $222.54 - $584.01 |
| Short Interest | 8.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.99 |
| Forward P/E | 18.9 |
| Current P/E | 19.8 |
| YoY Growth | 5.3% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 2.6% to 0.5% (-2.1% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 2.5pp (needs >3.0% for momentum thesis). MRS_5 at 1.1% confirms short-term momentum alignment. Below SMA200 (0.78x), long-term trend not supportive. MACD histogram positive (1.70), confirming momentum. OFD pattern: +SUL (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 0.53% (CS: 78) | Neutral |
| RSI_14 | 68.4 | Neutral |
| MACD Histogram | 1.70 | Bullish |
| vs SMA20 | 1.055x | Above |
| vs SMA50 | 1.063x | Above |
| vs SMA200 | 0.784x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $253.79
- **Stop Loss:** $241.75 (4.7% risk)
- **Target:** $265.83 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 95
- **Position Value:** $24,110.05
- **Portfolio %:** 24.11%
- **Risk Dollars:** $1,150.00
- **Risk Per Trade:** 1.15%
- **Modifiers:** L1 115% | L2 100% | Combined 1.15x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.15x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with selective risk appetite and defensive rotation. VIX at 14.2 (2nd percentile) signals low volatility, while positive yield curve (+58bps) and stable economic indicators support continued expansion. Market breadth at 58.7% shows decent participation, but rotation into defensive names and Fed liquidity concerns warrant measured positioning.*

### Earnings

**Next:** 2026-02-10 (Est: $3.51)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.43 | $2.76 | +13.7% |
| 2025Q2 | $3.31 | $3.53 | +6.8% |
| 2025Q1 | $2.72 | $2.98 | +9.7% |
| 2024Q4 | $3.26 | $5.45 | +67.2% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_10*